Business Context and Reporting Period
NLS Pharmaceutics Ltd., a Swiss foreign private issuer, filed this Form 6-K for June 2021. The report concerns the Ordinary Shareholders’ Meeting held on June 17, 2021. The filing identifies the registrant as NLS Pharmaceutics Ltd.; it does not reference Newcelx Ltd.
Meeting Outcome
A quorum was present, and shareholders approved all agenda items as originally proposed. The filing does not provide details of the individual resolutions or voting results.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Changes, Outlook, and Risks
The filing does not report material changes versus a prior period, financial guidance, management outlook, contingencies, unusual items, or specific risk factors.
Investor Verification Items
- Verify the registrant’s identity, as the supplied metadata names Newcelx Ltd. while the filing names NLS Pharmaceutics Ltd.
- Review the company’s related shareholder-meeting materials to confirm the agenda items approved and any voting results.
- Consult the company’s annual report and other filings for financial condition, operating performance, liquidity, and risk information not included in this Form 6-K.